LITERATURE
原始候选快照
v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。
| 论文 | 标识 | 日期 | 入排置信度 | 入排依据 | KM 状态 |
|---|---|---|---|---|---|
| Dupilumab Efficacy in Children With Eosinophilic Esophagitis With Prior Swallowed Topical Corticosteroid Use: A Subgroup Analysis.Am J Gastroenterol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 7 张 PMC Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 1.:非 KM 图;Figure 2.:非 KM 图;Figure 3.:非 KM 图;Figure 4.:非 KM 图;另有 2 张未列出。 | PMID 40531526PMC12947915 | 2026-Mar-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Long-term safety and tolerability of lumateperone 42 mg in patients with bipolar disorder: results from a 6-month open-label extension study.Int Clin Psychopharmacol入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40662488PMC12854352 | 2026-Mar-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Lumateperone monotherapy for major depressive episodes associated with bipolar disorder: efficacy and safety in a randomized placebo-controlled trial.Int Clin Psychopharmacol已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:森林图/亚组分析图。 | PMID 40694062PMC12854375 | 2026-Mar-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal squamous cell carcinoma: A multicenter, open-label, randomized, phase III clinical trial.Int J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41088876无 PMCID | 2026-Mar-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Simultaneous Integrated Dose Reduction Radiation Therapy Versus Conventional Fractionated Radiation Therapy With Chemotherapy for Limited-Stage Small Cell Lung Cancer in the Modern Treatment Era: A Phase 3, Randomized Clinical Trial (SDR-RT trial).Int J Radiat Oncol Biol Phys疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41101556无 PMCID | 2026-Mar-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Doravirine Resistance Patterns Identified Through Week 192 in the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 Clinical Trials.J Acquir Immune Defic SyndrPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41129125无 PMCID | 2026-Mar-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn's Disease.Inflamm Bowel DisPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41189093无 PMCID | 2026-Mar-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Age.Inflamm Bowel Dis疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1.:非 KM 图;Figure 2.:非 KM 图;Figure 3.:非 KM 图。 | PMID 41274280PMC12794806 | 2026-Mar-01 | 0.95 | Study is a Phase III randomized trial of a drug for ulcerative colitis (non-oncology). No time-to-event oncology endpoint (e.g., OS, PFS) is reported in the abstract; endpoints are clinical response rates (efficacy rates) and safety. | 无 KM 图 |
| Final Results of the ILLUMINATE-A Phase 3 Clinical Trial of Lumasiran for Primary Hyperoxaluria 1.Clin J Am Soc Nephrol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 1 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图。 | PMID 41343248PMC12959742 | 2026-Mar-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical Trial.JAMA Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41481311PMC12761762 | 2026-Mar-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Finerenone in People with CKD, Type 2 Diabetes, and History of Nephrectomy.Clin J Am Soc Nephrol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 1 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图。 | PMID 41533467PMC12959748 | 2026-Mar-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis who have a history of systemic therapies: a post hoc analysis of a phase III trial.Int ImmunopharmacolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41547249无 PMCID | 2026-Mar-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical Trial.JAMA Oncol | PMID 41609753PMC12856745 | 2026-Mar-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: A 52-Week Open-Label Extension Trial.Am J Psychiatry入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41634905无 PMCID | 2026-Mar-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study.Cancer Res Commun | PMID 41757470PMC13012029 | 2026-Mar-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial.Cancer Res Commun | PMID 41790036PMC13036839 | 2026-Mar-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Phase III study of Phlai capsules in the treatment of allergic rhinitis: A randomized, double-blind, placebo-controlled trial.Asian Pac J Allergy ImmunolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 37302097无 PMCID | 2026-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Upadacitinib Maintenance Therapy in Crohn's Disease: Final Results From the Randomized Phase 3 U-ENDURE Study.Clin Gastroenterol HepatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40738276无 PMCID | 2026-Mar | 0.95 | The study is a Phase III randomized trial of a drug (upadacitinib) in Crohn's disease (non-oncology). The primary efficacy endpoints are CDAI clinical remission and endoscopic response at week 52, which are not time-to-event endpoints (e.g., OS, PFS). No Kaplan-Meier curves or hazard ratios for a time-to-event outcome are reported. | 无 KM 图 |
| Efficacy and Safety of Extended-Release Acetazolamide Capsules for the Prevention of Acute Mountain Sickness: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial.High Alt Med BiolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40955751无 PMCID | 2026-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis.Arthritis Rheumatol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1:森林图/亚组分析图;Figure 2:森林图/亚组分析图;Figure 3:AI 判定为 other;Figure 4:森林图/亚组分析图。 | PMID 40977418PMC12991915 | 2026-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial.Diabetes Metab J已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig. 1.:AI 判定为 other;Fig. 2.:AI 判定为 other;Fig. 3.:AI 判定为 multi panel km;captionless-figure:AI 判定为 other。 | PMID 41151541PMC12996957 | 2026-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Long-term changes in hepatic reserve and prognosis after direct-acting antiviral treatment in patients with hepatitis C virus-related decompensated cirrhosis: a five-year follow-up study of a Japanese phase 3 trial.J Gastroenterol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41168423无 PMCID | 2026-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient-Reported Outcomes in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Withdrawal Trial.Arthritis Rheumatol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图;Figure 2:非 KM 图;Figure 3:非 KM 图;Figure 4:非 KM 图;Figure 5:AI 判定为 other。 | PMID 41169192PMC12991914 | 2026-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Population pharmacokinetics and exposure-response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study.Br J Clin Pharmacol | PMID 41222125PMC12930014 | 2026-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 部分完成 |
| Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension.J Am Acad DermatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41248770无 PMCID | 2026-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Dynamics of early electroencephalographic patterns and epileptic seizures in acute intracerebral hemorrhage: A prospective controlled study.Epilepsia已检查 2 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 other。 | PMID 41250972PMC13007832 | 2026-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41260259无 PMCID | 2026-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41260263无 PMCID | 2026-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41260264无 PMCID | 2026-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Repeated-dose behavioral intervention to reduce opioid overdose among overdose survivors with opioid use disorder: A two-site phase III randomized controlled trial.AddictionPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41261059无 PMCID | 2026-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Results of the MACiTEPH study of macitentan for the treatment of inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension.J Heart Lung TransplantPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41297734无 PMCID | 2026-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Immunogenicity, efficacy and safety of a biosimilar insulin glulisine compared with originator in adults with type 1 diabetes mellitus: A phase III randomised clinical trial.Diabetes Obes MetabPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41366610无 PMCID | 2026-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Exploring the impact of baseline and on-treatment variables on durability of responses to fostemsavir through weeks 96 and 192 in the phase 3 BRIGHTE study.HIV Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 forest plot;FIGURE 2:非 KM 图。 | PMID 41387279PMC12968507 | 2026-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and hypoglycaemia outcomes of once-weekly insulin icodec versus once-daily basal insulin comparators across baseline HbA1c, BMI and duration of type 2 diabetes subgroups: A post hoc analysis of ONWARDS 1-5.Diabetes Obes Metab已检查 2 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:森林图/亚组分析图;FIGURE 2:森林图/亚组分析图。 | PMID 41387317PMC12890738 | 2026-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| IMpower010: 5-Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB-IIIA Non-Small Cell Lung Cancer.Cancer Sci | PMID 41416818PMC12951087 | 2026-Mar | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double-blind, multicentre, therapeutic confirmatory phase 3 clinical trial.Diabetes Obes Metab已检查 3 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other。 | PMID 41417560PMC12890737 | 2026-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Perioperative Nivolumab in Resectable Non-Small Cell Lung Cancer: A Subanalysis of Japanese Patients From CheckMate 77T.Cancer Sci | PMID 41431434PMC12951114 | 2026-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial of lemborexant in adults with insomnia disorder.Sleep MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41442783无 PMCID | 2026-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| SARS-CoV-2 resistance analyses from the Phase 3 OAKTREE study of obeldesivir in low-risk nonhospitalized participants with COVID-19.Antiviral ResPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41475511无 PMCID | 2026-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of vunakizumab between super responders and non-super responders of patients with moderate-to-severe plaque psoriasis: a post-hoc exploratory analysis of a phase III trial.Naunyn Schmiedebergs Arch PharmacolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41483190无 PMCID | 2026-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and Safety of Aurantii Fructus Immaturus Flavonoid Tablets in Patients with Functional Dyspepsia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial.Chin J Integr MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41489782无 PMCID | 2026-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: Long-term Data from the SAKK 09/10 Randomised Phase 3 Trial.Eur Urol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41494929无 PMCID | 2026-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Phase 3 randomized clinical trials of simufilam in mild-to-moderate Alzheimer's disease.J Prev Alzheimers Dis已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:森林图/亚组分析图。 | PMID 41500915PMC12988371 | 2026-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis After Inadequate Response to Dupilumab: Efficacy and Safety Results from Period 2 of Phase 3b/4 Study (LEVEL UP).Am J Clin Dermatol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:非 KM 图。 | PMID 41533220PMC13033017 | 2026-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Genotype-stratified adjunctive dexamethasone for tuberculous meningitis in HIV-negative adults: a randomized controlled phase 3 trial.Nat Med | PMID 41540106PMC13004695 | 2026-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib.Clin Lung Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41544603无 PMCID | 2026-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Induction chemotherapy followed by chemoradiotherapy in patients with locally advanced anal cancers: The PRODIGE 85-FFCD 1804-KANALRAD trial.Dig Liver Dis疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41545254无 PMCID | 2026-Mar | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 无 KM 图 |
| Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study.Am J Hematol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:非 KM 图;FIGURE 3:非 KM 图;FIGURE 4:非 KM 图;FIGURE 5:非 KM 图。 | PMID 41549790PMC12868996 | 2026-Mar | 0.85 | The record describes a primary efficacy analysis from a Phase III randomized trial with a drug intervention in oncology (LR-MDS). However, the primary endpoint analyzed is RBC transfusion response, which is a categorical outcome (responder/non-responder), not a time-to-event endpoint like OS, PFS, DFS, etc. No Kaplan-Meier survival curves, hazard ratios, or time-to-event analyses are mentioned in the provided abstract. | 无 KM 图 |
| LDL-C Goal Attainment with Fixed-Dose Ezetimibe and Atorvastatin Versus High-Dose Atorvastatin in Chinese Patients: Subgroup Analysis of a Randomized Trial.Adv Ther已检查 1 张 PubMed Figure,均未识别为 KM 图:Fig. 1:森林图/亚组分析图。 | PMID 41553712PMC12999713 | 2026-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results.LeukemiaPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41555010无 PMCID | 2026-Mar | 0.95 | The record describes a Phase 3 randomized trial with a drug intervention and a primary time-to-event efficacy endpoint (treatment-free remission), meeting all inclusion criteria. | 无 KM 图 |